SCHEMBL30765703

SCHEMBL30765703

CC(C)(C)OC(=O)Cn1c(-c2ccccc2F)ncc(NC2(c3ccc4oc5ccccc5c4c3)CC2)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.34
NPSR1 Q6W5P4 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
JAK3 P52333 1/20 0.33
POLB P06746 2/20 0.32
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765812 0.89 HPGD (0.34) ALDH1A1HPGDNPSR1RXFP1POLB
SCHEMBL30765690 0.88 GAA (0.40) ALDH1A1HPGDNPSR1RXFP1POLB
SCHEMBL30765963 0.84 GABRP (0.37) ALDH1A1HPGDKDM4ENPSR1RXFP1
SCHEMBL30765975 0.82 ALDH1A1 (0.35) ALDH1A1HPGDKDM4ENPSR1RXFP1
SCHEMBL31558585 0.82 ALDH1A1 (0.35) ALDH1A1HPGDKDM4ENPSR1RXFP1
SCHEMBL30765722 0.82 ELANE (0.35) ALDH1A1HPGDKDM4ENPSR1RXFP1
SCHEMBL30765701 0.80 ALDH1A1 (0.35) ALDH1A1HPGDKDM4ENPSR1JAK2
SCHEMBL30765672 0.79 ALDH1A1 (0.33) ALDH1A1HPGDKDM4ENPSR1RXFP1
SCHEMBL30765861 0.78 F3 (0.36) ALDH1A1HPGDLMNA
SCHEMBL30765964 0.74 GABRP (0.38) ALDH1A1HPGDNPSR1RXFP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed